Sign In
Buy LGND
$234.40
+1.64 (+0.705%)
At Close: Jun 03, 2026
Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript
03:47am, Wednesday, 10'th Dec 2025
Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
07:00am, Tuesday, 09'th Dec 2025
Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over
Tweedy Browne's Strategic Moves: Alphabet Inc. Sees a -1.43% Portfolio Impact
10:01am, Thursday, 20'th Nov 2025
Exploring Tweedy Browne (Trades, Portfolio)'s Recent 13F Filing and Investment Adjustments Tweedy Browne (Trades, Portfolio) recently submitted its 13F filing
This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know
02:20pm, Monday, 17'th Nov 2025
Delaware-based Ashford Capital Management sold 58,097 shares of Ligand Pharmaceuticals for an estimated $8.9 million in the third quarter. The transaction value equaled about 1% of 13F reportable asse
Envestnet Asset Management Inc. Acquires 769 Shares of Ligand Pharmaceuticals Incorporated $LGND
04:26am, Sunday, 16'th Nov 2025
Envestnet Asset Management Inc. boosted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 2.9% during the undefined quarter, according to the company in its most recent disclosure
Private Capital's Strategic Moves: Spotlight on Matthews International Corp
05:03pm, Friday, 14'th Nov 2025
Insights from Private Capital (Trades, Portfolio)'s Third Quarter 2025 13F Filing Private Capital (Trades, Portfolio) recently submitted its 13F filing for the
Ligand Pharmaceuticals: Superb Q3/2025 With Second Guidance Raise Heralds Good Things To Come
10:10am, Thursday, 13'th Nov 2025
Ligand Pharmaceuticals (LGND) continues to deliver strong returns, with shares up approximately 74% since my last 'Buy' rating in June 2025. LGND's attractive royalty-based business model remains a ke
Ligand Pharmaceuticals Incorporated (LGND) Q3 2025 Earnings Call Transcript
04:56pm, Saturday, 08'th Nov 2025
Ligand Pharmaceuticals Incorporated ( LGND ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Melanie Herman Todd Davis - CEO & Director Lauren Hay Octavio Espinoza - Chief Fina
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
07:00am, Thursday, 06'th Nov 2025
Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) a
Ligand to Participate in November Investor Conferences
04:01pm, Thursday, 30'th Oct 2025
JUPITER, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza wi
Impax Small Cap Fund Q3 2025 Contributors And Detractors
04:26pm, Tuesday, 28'th Oct 2025
Ligand Pharmaceuticals (LGND) (Health Care, Pharmaceuticals) shares rose after announcing adjusted earnings per share that came in ahead of consensus. Acadian Asset Management (AAMI) (Financials, Asse
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025
07:00am, Thursday, 23'rd Oct 2025
JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 20
Yousif Capital Management LLC Has $828,000 Stock Position in Ligand Pharmaceuticals Incorporated $LGND
04:36am, Thursday, 23'rd Oct 2025
Yousif Capital Management LLC grew its position in Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) by 3.9% in the undefined quarter, according to its most recent filing with the SEC. The firm owned
Ligand to Host Investor Day on December 9, 2025
07:00am, Thursday, 16'th Oct 2025
JUPITER, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place in New York City on Tuesday, December 9
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
07:00am, Thursday, 09'th Oct 2025
Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17 th Captisol-enabled™ approved product JUPITER, Fl
